Ocular Therapeutix
OCUL
79 hedge funds and large institutions have $99.6M invested in Ocular Therapeutix in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 13 closing their positions.
555% more call options, than puts
Call options by funds: $1.22M | Put options by funds: $186K
42% more capital invested
Capital invested by funds: $70.2M → $99.6M (+$29.3M)
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
5% more funds holding
Funds holding: 75 → 79 (+4)
3.5% more ownership
Funds ownership: 48.92% → 52.42% (+3.5%)
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.11M |
| 2 |
DAM
Deltec Asset Management
New York
|
+$398K |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$373K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$195K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$193K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$3.99M |
| 2 |
BlackRock
New York
|
-$847K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$412K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$315K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$203K |
OCUL Hedge Fund Activity: Q4 2019 in Review
79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2019, worth a combined $99.6M — up 42% from $70.2M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new OCUL positions and 13 closed out — a net gain of 4 holders — while 22 added to existing stakes and 21 trimmed.
The largest buyer was Opaleye Management, adding an estimated $8.11M. The largest seller was Man Group, cutting an estimated $3.99M.
- 79 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2019, up from 75 in Q3 2019.
- Funds reported $99.6M of Ocular Therapeutix stock for Q4 2019, up 42% quarter-over-quarter.
- 17 funds opened new Ocular Therapeutix positions in Q4 2019 and 13 closed out, a net change of +4 holders.
- The largest Ocular Therapeutix buyer in Q4 2019 was Opaleye Management, an estimated $8.11M added.
- The largest Ocular Therapeutix seller in Q4 2019 was Man Group, an estimated $3.99M sold.
Based on aggregated 13F filings for Q4 2019.